Edition:
India

Profile: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

47.16USD
7 Aug 2020
Change (% chg)

$0.85 (+1.84%)
Prev Close
$46.31
Open
$46.25
Day's High
$47.35
Day's Low
$46.07
Volume
57,379
Avg. Vol
76,536
52-wk High
$75.15
52-wk Low
$38.41

Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305 and EDP-938.

Paritaprevir

The Company's Paritaprevir product is an NS3/4A protease inhibitor. The Company's product, Paritaprevir, is a DAA in VIEKIRA PAK and the other treatment regimens.

ABT-493

The Company is developing its second protease inhibitor, glecaprevir (ABT-493). AbbVie has co-formulated ABT-493 with its second NS5A inhibitor, pibrentasvir (ABT-530), and is developing them as its next combination, which is referred to as G/P, for HCV treatment. G/P would be a pan-genotypic, once daily, all oral, fixed-dose combination treatment for HCV. ABT-493 has completed various Phase III registrational studies in combination with ABT-530.

EDP-305

The Company's EDP-305 is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC. EDP-305 is in Phase I clinical development.

EDP-938

The Company's EDP-938 is a clinical candidate for RSV. EDP-938 is in preclinical development.

The Company competes with Gilead, Bristol-Myers Squibb, Merck, Johnson & Johnson, Co-Crystal Pharma, Microbio Co., Regulus, Roche, Taigen, Trek, Alberio, Arisaph, Astra-Zeneca, BMS, Cempra, Conatus, Galectin, Galmed, GlaxoSmithKline, Immuron, Medicinova, Novartis, NGM, Novo Nordisk, Octeta, Shire, Tobira/Allergan, Boehringer Ingelheim, Can-Fite Biopharma, Cymabay, Durect, Genkyotex, Ionis, Islet, Viking, Ablynx, Ark Biosciences, Medivir, Pulmocide, ReViral, Arrowhead Pharmaceuticals, Maxwell, Janssen, Replicor, Spring Bank, Alnylam, Arbutus, Assembly, Enyo and Benitec.

Company Address

Enanta Pharmaceuticals Inc

500 Arsenal St
WATERTOWN   MA   02472-2806
P: +1617.6070800
F: +1617.6070530

Company Web Links